CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...
Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law
Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...
Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...
Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies
Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...
Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...
YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam
China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...